Discontinued — last reported Q4 '25
Eli Lilly Net Change in Cash increased by 2170.3% to $6.42B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4312.7%, from $145.40M to $6.42B. Over 2 years (FY 2021 to FY 2023), Net Change in Cash shows an upward trend with a 115.8% CAGR.
An increase suggests the company is accumulating liquidity, while a decrease indicates it spent more on operations, investments, or debt/shareholder returns than it brought in. For mature tech firms, a decrease often signals aggressive capital expenditure or heavy share repurchases rather than operational weakness.
The total change in a company's cash, cash equivalents, and restricted cash over a specific reporting period. It is the...
At large-cap technology peers, this figure is often highly influenced by the timing of multi-billion dollar acquisitions, the scale of data center infrastructure investment, and the pace of share buyback programs.
cf_net_change_in_cash| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $217.60M | $568.20M | $30.30M | -$1.36B | $163.70M | -$5.50M | -$550.40M | $1.48B | -$851.40M | -$313.70M | $437.80M | -$358.40M | $763.40M | $145.40M | -$175.10M | $282.60M | $6.42B |
| QoQ Change | — | +161.1% | -94.7% | <-999% | +112.0% | -103.4% | <-999% | +368.7% | -157.6% | +63.2% | +239.6% | -181.9% | +313.0% | -81.0% | -220.4% | +261.4% | >999% |
| YoY Change | — | — | — | — | -24.8% | -101.0% | <-999% | +208.8% | -620.1% | <-999% | +179.5% | -124.2% | +189.7% | +146.4% | +51.1% | -63.0% | >999% |
We use cookies for analytics. See our Privacy and Cookie Policy.